16th Jul 2009 15:39
Proteome Sciences plc
("Proteome" or the "Company")
Holding(s) in Company
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii |
Proteome Sciences plc |
||
2 Reason for the notification (please tick the appropriate box or boxes): |
|||
An acquisition or disposal of voting rights |
Yes |
||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
No |
||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
No |
||
An event changing the breakdown of voting rights |
No |
||
Other (please specify): |
No |
||
3. Full name of person(s) subject to the notification obligation: iii |
Cubana Investments Limited |
||
4. Full name of shareholder(s) (if different from 3.):iv |
|||
5. Date of the transaction and date on which the threshold is crossed or reached: v |
19th June 2009 |
||
6. Date on which issuer notified: |
15th July 2009 |
||
7. Threshold(s) that is/are crossed or reached: vi, vii |
>11% |
8. Notified details: |
|||||||||||||||||
A: Voting rights attached to shares viii, ix |
|||||||||||||||||
Class/type of shares if possible using the ISIN CODE |
Situation previous to the triggering transaction |
Resulting situation after the triggering transaction |
|||||||||||||||
Number of Shares |
Number of Voting Rights |
Number of shares |
Number of voting rights |
% of voting rights x |
|||||||||||||
Direct |
Direct xi |
Indirect xii |
Direct |
Indirect |
|||||||||||||
GB0003104196 |
13,287,183 |
13,287,183 |
15,187,465 |
15,187,465 |
11.44% |
||||||||||||
B: Qualifying Financial Instruments |
|||||||||||||||||
Resulting situation after the triggering transaction |
|||||||||||||||||
Type of financial instrument |
Expiration date xiii |
Exercise/ Conversion Period xiv |
Number of voting rights that may be acquired if the instrument is exercised/ converted. |
% of voting rights |
|||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi |
|||||||||||||||||
Resulting situation after the triggering transaction |
|||||||||||||||||
Type of financial instrument |
Exercise price |
Expiration date xvii |
Exercise/ Conversion period xviii |
Number of voting rights instrument refers to |
% of voting rights xix, xx |
||||||||||||
Nominal |
Delta |
||||||||||||||||
Total (A+B+C) |
|||||||||||||||||
Number of voting rights |
Percentage of voting rights |
||||||||||||||||
15,187,465 |
11.44% |
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi |
|
Proxy Voting: |
|
10. Name of the proxy holder: |
|
11. Number of voting rights proxy holder will cease to hold: |
|
12. Date on which proxy holder will cease to hold voting rights: |
|
13. Additional information: |
|
14. Contact Name: |
Mirza Rahman |
15. Contact telephone: |
+65 6538 1998 |
Enquiries:
Proteome Sciences plc (01932 865 065) Christopher Pearce, CEO
James Malthouse, FD
Noble & Company Limited (020 7763 2200)John Llewellyn-Lloyd
Sam Reynolds
Related Shares:
Proteome